Gastroenterology
Volume 122, Issue 5 , Pages 1500-1511, May 2002

The burden of selected digestive diseases in the United States☆☆

  • Robert S. Sandler

      Affiliations

    • University of North Carolina, Chapel Hill, North Carolina
  • ,
  • James E. Everhart

      Affiliations

    • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
  • ,
  • Mark Donowitz

      Affiliations

    • Johns Hopkins University, Baltimore, Maryland
  • ,
  • Elizabeth Adams

      Affiliations

    • American Gastroenterological Association, Bethesda, Maryland
  • ,
  • Kelly Cronin

      Affiliations

    • The Lewin Group, Falls Church, Virginia
  • ,
  • Clifford Goodman

      Affiliations

    • The Lewin Group, Falls Church, Virginia
  • ,
  • Eric Gemmen

      Affiliations

    • The Lewin Group, Falls Church, Virginia
  • ,
  • Shefali Shah

      Affiliations

    • The Lewin Group, Falls Church, Virginia
  • ,
  • Aida Avdic

      Affiliations

    • The Lewin Group, Falls Church, Virginia
  • ,
  • Robert Rubin

      Affiliations

    • The Lewin Group, Falls Church, Virginia
    • Division of Nephrology and Hypertension, Georgetown University School of Medicine, Washington, DC

Received 21 September 2001; accepted 3 January 2002.

Abstract 

Background & Aims: Gastrointestinal (GI) and liver diseases inflict a heavy economic burden. Although the burden is considerable, current and accessible information on the prevalence, morbidity, and cost is sparse. This study was undertaken to estimate the economic burden of GI and liver disease in the United States for use by policy makers, health care providers, and the public. Methods: Data were extracted from a number of publicly available and proprietary national databases to determine the prevalence, direct costs, and indirect costs for 17 selected GI and liver diseases. Indirect cost calculations were purposefully very conservative. These costs were compared with National Institutes of Health (NIH) research expenditures for selected GI and liver diseases. Results: The most prevalent diseases were non–food-borne gastroenteritis (135 million cases/year), food-borne illness (76 million), gastroesophageal reflux disease (GERD; 19 million), and irritable bowel syndrome (IBS; 15 million). The disease with the highest annual direct costs in the United States was GERD ($9.3 billion), followed by gallbladder disease ($5.8 billion), colorectal cancer ($4.8 billion), and peptic ulcer disease ($3.1 billion). The estimated direct costs for these 17 diseases in 1998 dollars were $36.0 billion, with estimated indirect costs of $22.8 billion. The estimated direct costs for all digestive diseases were $85.5 billion. Total NIH research expenditures were $676 million in 2000. Conclusions: GI and liver diseases exact heavy economic and social costs in the United States. Understanding the prevalence and costs of these diseases is important to help set priorities to reduce the burden of illness.

GASTROENTEROLOGY 2002;122:1500-1511

Abbreviations:  GERD , gastroesophageal reflux disease, GHC , Group Health Cooperative of Puget Sound, GI , gastrointestinal, IBS , irritable bowel syndrome, ICD-9 , International Classification of Diseases, 9th Revision, MEPS , Medical Expenditure Panel Survey, NAMCS , National Ambulatory Medical Care Survey, NHAMCS , National Hospital Ambulatory Medical Care Survey, NHDS , National Hospital Discharge Survey, NHIS , National Health Interview Survey, NIH , National Institutes of Health, NIS , nationwide inpatient sample, OPD , outpatient department, SAF , Medicare standard analytic files

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Address requests for reprints to: Robert S. Sandler, M.D., M.P.H., CB# 7080, 719 Burnett-Womack Building, University of North Carolina, Chapel Hill, North Carolina 27599-7080. e-mail rsandler@med.unc.edu; fax (919) 966-2478.

☆☆ Supported by an unrestricted grant from TAP Pharmaceutical Products, Inc. to the American Gastroenterological Association.

PII: S0016-5085(02)74965-2

Gastroenterology
Volume 122, Issue 5 , Pages 1500-1511, May 2002